SCHEMBL6315215

SCHEMBL6315215

COc1ccc(OC)c(C(=O)C2CC2c2ccc(N(C)C)c(OOP(=O)(O)O)c2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
APP P05067 2/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TUBB1 Q9H4B7 1/20 0.35
KDM1A O60341 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC9A1 P19634 1/20 0.34
ALDH1A1 P00352 3/20 0.34
ABCG2 Q9UNQ0 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316373 0.94 MAPT (0.37) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6317115 0.92 MAPT (0.35) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6314117 0.91 KDM1A (0.37) MAPTKDM4ELMNAHTTNPSR1
SCHEMBL6316492 0.90 MAPT (0.35) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6314453 0.90 MAPT (0.43) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6315633 0.87 MAPT (0.41) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6315434 0.87 MAPT (0.41) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6315313 0.84 MAPT (0.41) MAPTL3MBTL1KDM4ELMNAHTT
SCHEMBL6317758 0.83 TUBB4A (0.41) MAPTL3MBTL1APPKDM4ELMNA
SCHEMBL6314713 0.83 MAPT (0.35) MAPTKDM4ELMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887904-B2 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-05-03 US disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885L3MBTL1 3439/4885APP 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.